肿瘤细胞治疗研究
英文原题：RORing CAR T Cells in Solid and Hematologic Cancers: Same but Different.
最近一项 I 期临床研究在慢性淋巴细胞白血病、非小细胞肺癌和三阴性乳腺癌患者中测试了抗 ROR1 嵌合抗原受体（CAR）T 细胞。
近期一项I期临床研究在慢性淋巴细胞白血病、非小细胞肺癌和三阴性乳腺癌患者中测试了抗ROR1嵌合抗原受体（CAR）T细胞。该产品可安全给药，在慢性淋巴细胞白血病中显示活性，但在非小细胞肺癌和三阴性乳腺癌中的活性较低。详见Jaeger-Ruckstuhl等人相关文章，第503页。
A recent phase I clinical study tested anti-ROR1 chimeric antigen receptor (CAR) T cells in patients with chronic lymphocytic leukemia, non-small cell lung cancer, and triple-negative breast cancer. The product could be safely administered and had activity in chronic lymphocytic leukemia but less so in non-small cell lung cancer and triple-negative breast cancer. See related article by Jaeger-Ruckstuhl et al., p. 503.
MEMBER ACCOUNT
登录成功会直接打开下一页。
